Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes

AIMS: To investigate the association of novel oral glucose‐lowering drugs (GLDs), compared with that of insulin, with risk of all‐cause mortality, cardiovascular disease (CVD) and severe hypoglycaemia. METHODS: During 2013 to 2014 all patients with type 2 diabetes in Sweden identified as new users o...

Descripción completa

Detalles Bibliográficos
Autores principales: Nyström, Thomas, Bodegard, Johan, Nathanson, David, Thuresson, Marcus, Norhammar, Anna, Eriksson, Jan W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485030/
https://www.ncbi.nlm.nih.gov/pubmed/28116795
http://dx.doi.org/10.1111/dom.12889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5485030/
https://www.ncbi.nlm.nih.gov/pubmed/28116795
http://dx.doi.org/10.1111/dom.12889

Ejemplares similares